Nortrel 1/35 28

Quick links

Choose a section

Quick links to important sections

Advertisements

Nortrel 1/35 28

Advertisements
Advertisements

Method of action: Estrogen, Progestin Combination

Advertisements

Overview of Nortrel 1/35 28

Property Description
Active Ingredients Norethindrone and Ethinyl Estradiol
Form Oral Tablet (Monophasic)
Pharmacological Class Sex Hormone Combination, Contraceptive
Common Use Prevention of Pregnancy
Origin Synthetic Hormones

Nortrel 1/35 28: Defining the Combined Oral Contraceptive

Nortrel 1/35 28 is classified as a Combined Oral Contraceptive (COC), a prescription-only medication that belongs to the pharmacological class of Sex Hormone Combinations. Its single defined purpose is the prevention of pregnancy, a use that is broadly clinically recognized and supported by extensive pharmacological studies. The medication is a synthetic product, utilizing manufactured hormonal compounds for therapeutic effect. The combination of Ethinyl Estradiol and Norethindrone in combined oral contraceptives is recognized by the World Health Organization as an essential medicine, underscoring its established efficacy in family planning.

Composition and Monophasic Tablet Form

The pharmaceutical preparation is a fixed-dose combination product containing two synthetic active ingredients: Ethinyl Estradiol, which functions as an estrogen, and Norethindrone, which acts as a progestin. Nortrel 1/35 28 is presented as an oral tablet provided in a 28-day regimen. It is specifically defined as monophasic, a characteristic meaning the 21 active tablets consistently deliver the exact same concentration of both hormonal ingredients throughout the cycle, a key differentiating feature from multiphasic preparations. This combination functions as a contraceptive agent by inhibiting ovulation.

Mechanism Principles for Conception Prevention

The efficacy of this combined hormonal preparation is achieved through a multi-layered physiological strategy aimed at establishing a continuous barrier against conception, a methodology that is well-established in reproductive medicine. The primary action involves the systemic suppression of signals that lead to the inhibition of ovulation, preventing the monthly release of an egg. Concurrently, the hormonal components induce a pronounced thickening of cervical mucus, which creates a physical impediment to sperm movement. Furthermore, the drug causes an alteration of the endometrium, rendering the uterine lining less receptive to the implantation of a fertilized egg, ensuring a multi-faceted and highly reliable approach to contraception.

Regulatory References

  1. FDA Label (Norethindrone/Ethinyl Estradiol)
  2. WHO Essential Medicines List (Ethinylestradiol)
  3. WHO Essential Medicines List
Advertisements

What side effects are possible with Nortrel 1/35 28?

Possible Side Effects and Safety Information

The safety profile for this combined oral contraceptive, which contains Norethindrone and Ethinyl Estradiol, is formally documented in regulatory texts and is organized by frequency and physiological system. This information outlines the officially recognized risks without providing clinical advice.


Common Adverse Reactions

Adverse effects listed as common or very common in regulatory prescribing information typically involve the Nervous System and Reproductive System and may include headache, nausea, breast tenderness, abdominal pain, and irregular uterine bleeding (spotting or breakthrough bleeding). Changes in weight and disturbances in mood are also documented as frequent hormonal effects.


Serious Adverse Reactions and Safety Constraints

The most clinically significant adverse reactions officially documented are vascular thromboembolic events. These rare but serious risks include Venous Thromboembolism (VTE), Pulmonary Embolism, Stroke, and Myocardial Infarction. The risk of VTE is noted to be highest during the first year of initial use or when restarting after a break.

The medicine is subject to safety restrictions and is contraindicated in women with an existing history of thrombotic disorders, severe uncontrolled Hypertension, or certain hepatic diseases (e.g., hepatic tumors). Furthermore, the risk of serious cardiovascular events is emphasized as being greatest in women over 35 years of age who smoke. These constraints define the boundaries under which the drug's established risk profile applies.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding overdose of Nortrel 1/35 28 (Norethindrone and Ethinyl Estradiol) is based exclusively on official government regulatory documents, which define the expected manifestations and required emergency procedures.

Domain Official Regulatory Documentation
Documented Overdose Presentations Nausea; Withdrawal bleeding (may occur in females).
Population-Specific Overdose Notes Serious ill effects have not been reported following acute ingestion of large doses by young children.
Emergency-Response Statements Contact a Poison Control Center; Seek emergency medical attention.

The official overdose profile for this combined oral contraceptive is generally characterized by limited reported clinical signs, primarily involving the gastrointestinal and reproductive systems.

Required Emergency Actions

In the event of a known or suspected overdose, regulatory guidance mandates that immediate medical help must be sought. Individuals must contact a Poison Control Center or seek emergency medical attention right away for guidance and evaluation. Management is generally described as symptomatic and supportive treatment, as the official prescribing information does not specify a known antidote for this combination product. This instruction to seek help is required regardless of the manifestation of symptoms.

Advertisements

Therapeutic Uses of Nortrel 1/35 28

The medication is primarily used to support women in their need for continuous pregnancy prevention. Beyond its main role, it is also relevant for easing certain gynecological and dermatological symptom patterns. This type of combined oral contraceptive is generally relevant for easing heavy or irregular menstruation and certain symptomatic discomforts.

Therapeutic Scope and Patient Benefits

Nortrel 1/35 28 is commonly used to provide pregnancy prevention for women seeking continuous fertility control. Additionally, it is relevant for managing symptom clusters that may become intense or disruptive, such as heavy menstrual bleeding and severe painful cramping. This use supports patients during difficult episodes by easing distress and supports general well-being during symptomatic phases.

This therapeutic approach is often applied in clinical settings where supportive symptom management is appropriate, especially when conditions involve recurrent or episodic manifestations. It assists with maintaining functional stability by managing symptoms that interfere with routine activities.

Quick Fact: Relief for Painful Menstruation
The medication supports patients by managing the discomfort associated with severe menstrual cramping.

Contraception and Proactive Family Planning

The medication supports the patient's choices regarding long-term planning.

Easing Menstrual Distress and Irregularity

Nortrel 1/35 28 is relevant for managing symptom clusters that may become intense or disruptive, such as heavy menstrual bleeding and severe painful cramping. This is a therapeutic domain distinct from other symptomatic relief contexts.

Therapeutic Support for Moderate Hormonal Acne

This medication is applied across domains where additional symptomatic support is needed for moderate acne in women. The use may assist with managing symptoms and provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus Drug Information overview
Advertisements

Eligibility and Restrictions for Use

The eligibility for Nortrel 1/35 28 (norethindrone and ethinyl estradiol) is strictly defined by regulatory documents, with absolute prohibitions based on thromboembolic risk and hormone-sensitive cancers.


Eligibility Scope

Category Regulatory Status & Statement
Populations for whom use is allowed Females of reproductive potential seeking pregnancy prevention [Source 1.5].
Populations for whom use is not recommended Females who are breastfeeding; females less than four weeks postpartum [Source 1.4, 2.7].
Populations for whom use is contraindicated Females over age 35 who smoke; current or history of DVT or PE; history of cerebral or coronary artery disease; breast cancer or other hormone-sensitive cancers; hepatic tumors or severe liver disease [Source 1.1, 1.3].

Official Eligibility Statements

  • Contraindication: The medicine is strictly prohibited for any female with uncontrolled hypertension, complicated diabetes with vascular involvement, or specific types of migraines with aura [Source 1.1, 1.4].
  • Restricted Use: The medicine must be discontinued at least four weeks before and for two weeks after major surgery or periods of prolonged immobilization [Source 1.1, 1.4].
  • Age/Condition: Use is formally indicated for pregnancy prevention and for moderate acne in post-menarcheal females aged 15 and older [Source 2.3]. Use is not indicated for post-menopausal women [Source 2.4].
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Nortrel 1/35 28 focuses on substances that alter hormone exposure or present specific safety prohibitions.


Formal Contraindicated Combinations

Co-administration is strictly prohibited with certain medicinal products as documented in regulatory labeling. Combinations including ombitasvir/paritaprevir/ritonavir (with or without dasabuvir) are contraindicated due to the risk of significant liver enzyme (ALT) elevations. Co-administration is also contraindicated with Fezolinetant and oral Tranexamic Acid, the latter due to a documented increase in thrombotic risk.


Exposure-Altering Pharmacokinetic Interactions

The most common documented interaction mechanism involves Metabolic Enzyme Interference.

Interaction Type Interacting Substances (Examples) Official Outcome
Decreased COC Exposure CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine), St. John’s wort Diminished contraceptive plasma concentration and potential for reduced effectiveness.
Increased COC Exposure CYP3A4 Inhibitors (e.g., Itraconazole), Grapefruit Juice Increased plasma concentration of the hormone components.

Timing and Reciprocal Drug Effects

Specific timing rules are documented for certain co-administered drugs. To minimize a reduction in Ethinyl Estradiol exposure, the contraceptive must be administered at least 4 hours prior to or 4 hours after the bile acid sequestrant Colesevelam. Furthermore, the contraceptive can affect the plasma concentrations of other medicines, officially decreasing the exposure of drugs like Lamotrigine and increasing the exposure of substrates like Tizanidine.

Advertisements

Mechanism of Action

The combined oral contraceptive, Nortrel 1/35 28, comprises the synthetic progestin norethindrone and the synthetic estrogen ethinyl estradiol. Its action is mediated through three principal pharmacodynamic mechanisms.

  1. Inhibition of Ovulation: The synthetic hormones exert negative feedback on the hypothalamus and pituitary gland, key components of the Hypothalamic-Pituitary-Ovarian (HPO) axis. This action suppresses the midcycle surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, thereby inhibiting follicular maturation and the subsequent release of an ovum (anovulation).
  2. Endometrial Alterations: The progestin component modulates cellular processes and glandular secretions within the endometrium. This results in a modified proliferative phase, which structurally and functionally renders the endometrium less receptive to embryonic implantation.
  3. Cervical Mucus Modification: The pharmacologic action increases cervical mucus viscosity. This higher resistance impedes sperm motility and transit, creating a biophysical barrier against passage through the cervix into the upper reproductive tract.
Advertisements

Dosage and Administration Information

Nortrel 1/35 28 is administered through the oral route as a daily tablet, a fundamental instruction that structures its use. The standard adult dosing regimen is one tablet taken every day, maintaining a continuous 24-hour interval between doses. This product is defined by its 28-day cyclic schedule, which consists of 21 consecutive days of the hormonally active compound (1 mg Norethindrone and 0.035 mg Ethinyl Estradiol) followed by 7 consecutive days of hormonally inert tablets.


Administration Context and Consistency

The core principle for proper administration is daily consistency. Standard instructions specify that the tablet be taken at the same time every day, a procedure designed to maintain consistent systemic levels of the medication. The medication may be taken regardless of whether it is with or without food.

Initial use of the medication is governed by specific starting protocols, either the Day 1 Start (beginning on the first day of the menstrual period) or the Sunday Start (beginning on the first Sunday after the menstrual period starts). For all females of reproductive potential, including postpubertal adolescents, proper administration requires adherence to these cyclic and timing constraints.


Missed Dosing Protocol

Official labeling contains precise rules for the high-level management of missed active tablets in the pack. These protocols generally require the user to take a missed tablet as soon as possible and, depending on the week of the cycle, may mandate the temporary use of a non-hormonal back-up method for the subsequent seven days to ensure that the required level of administration consistency is reestablished.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

Nortrel 1/35 28 is a combination oral contraceptive containing 1 mg of norethindrone (a progestin) and 35 mcg of ethinyl estradiol (an estrogen). Clinical data concerning this specific formulation focuses primarily on its established use in preventing pregnancy.


Efficacy and Mechanism

Research indicates that combination oral contraceptives primarily prevent pregnancy through inhibiting ovulation, thus suppressing the luteinizing hormone (LH) surge. Additional effects, such as altering cervical mucus to hinder sperm entry and modifying the endometrial lining, further contribute to its contraceptive action. When used consistently and correctly, this hormonal combination demonstrates high effectiveness in clinical settings.


Tolerability and Study Scope

Studies examining the tolerability of this drug generally report common, non-serious adverse events such as nausea, headache, and breakthrough bleeding. These effects are often most noticeable during the initial months of use.

Research has also evaluated the relationship between the use of combined oral contraceptives and potential serious risks. These risks, while rare in healthy non-smoking individuals, include venous thromboembolism (VTE), stroke, and myocardial infarction. Clinical data confirms that the risk of these serious events is significantly elevated in patients who smoke, particularly those over the age of 35.

The drug is also investigated for non-contraceptive benefits, which may include managing menstrual irregularities and conditions like acne, often stemming from the hormonal regulation it provides.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Nortrel 1/35 28 (FAQ)

Q: Is Nortrel 1/35 28 considered a 'low dose' or 'regular dose' pill?

The active tablets contain 0.035 mg of the estrogen component, Ethinyl Estradiol. In official regulatory texts, this concentration is generally considered a standard or mid-range dose for combined oral contraceptives.


Q: Is it normal to have spotting when first starting Nortrel 1/35 28?

Irregular uterine bleeding, which includes spotting or breakthrough bleeding, is listed in the official product information as a common adverse reaction. This may be observed during the initial months of use.


Q: How long does it typically take for Nortrel 1/35 28 to fully start working?

Regulatory labeling indicates that a back-up method is generally recommended during the first seven days of active tablet use, as contraceptive effectiveness is achieved after this period. A non-hormonal back-up method is often advised during this initial period.


Q: Can Nortrel 1/35 28 cause changes in mood or anxiety levels?

The possibility of mood changes or emotional disorders, including depression, is formally documented in the safety information for this class of medication.


Q: What is the risk of blood clots associated with Nortrel 1/35 28?

Official safety information states that combined oral contraceptives (COCs) carry a risk of rare but serious vascular events, such as venous thromboembolism (VTE), which are blood clots. This risk is generally highest during the first year of initial use or when restarting after a break.


Q: What should I know about taking Nortrel 1/35 28 if I also take anti-seizure medication?

Some anti-seizure medications, such as Carbamazepine and Phenytoin, are known to act as metabolic enzyme inducers that can decrease the concentration of contraceptive hormones, potentially reducing effectiveness. The use of a non-hormonal back-up method may be recommended when taking certain interacting drugs, as they can reduce the pill's effectiveness.


Q: Is it normal to have a very light period or no period on Nortrel 1/35 28?

The medication alters the lining of the uterus. As a result, changes in expected vaginal bleeding, including very light or even missed periods (amenorrhea), are listed in the official safety information as possible side effects.


Q: Can Nortrel 1/35 28 be used by women who have a history of migraines?

Official prescribing information states that the medication is prohibited for females with a history of migraines accompanied by neurological symptoms, such as an aura. This is listed as a contraindication.


Q: Is a breakthrough bleeding that lasts for several months considered normal when using Nortrel 1/35 28?

Breakthrough bleeding is common, especially during the first few cycles of use. Regulatory text notes that if undiagnosed, persistent, or recurrent abnormal bleeding continues, other potential medical causes should be investigated.


Q: Are the inactive pills in Nortrel 1/35 28 just sugar pills?

The white tablets in the 28-day package are hormonally inert, meaning they do not contain the active Norethindrone and Ethinyl Estradiol. They contain non-hormonal ingredients and do not serve a therapeutic purpose.


Q: Can taking Nortrel 1/35 28 affect my weight?

Weight changes (gain or loss) are listed in the official adverse reactions section as a possible common side effect associated with the use of this drug.


Q: Does Nortrel 1/35 28 stop ovulation completely?

The primary mechanism of action is the systemic suppression of signals that trigger the release of an egg, known as inhibiting ovulation (anovulation). This action is the primary mechanism of contraception.


Q: Does grapefruit juice interact with Nortrel 1/35 28?

Yes, regulatory information indicates that grapefruit juice can act as an inhibitor of the CYP3A4 enzyme system. This may lead to increased plasma concentrations of the hormone components of the contraceptive.


Q: Is the progestin in Nortrel 1/35 28 considered a first, second, or third-generation type?

The progestin component in Nortrel 1/35 28 is norethindrone. While the specific generational classification may not be explicitly stated in the label, the chemical name and its concentration are detailed in the official description.


Q: What is the mechanism by which birth control pills like Nortrel 1/35 28 can manage heavy periods?

Official non-contraceptive health benefit sections indicate that use of combined oral contraceptives is associated with a reduction in menstrual blood loss. This can lead to a decreased incidence of iron deficiency anemia.


Q: Why do some people experience breast tenderness when starting this pill?

Breast tenderness is listed as a common adverse reaction in the official safety information. This effect is a recognized result of the body’s response to the synthetic hormones in the pill.


Q: Is it true that Nortrel 1/35 28 can help protect against ovarian cancer?

Official health benefit sections indicate that the use of combined oral contraceptives is associated with a decreased risk of ovarian cancer.


Q: Can certain herbal teas or detox drinks reduce the effectiveness of Nortrel 1/35 28?

The label specifically notes that the herbal product St. John’s wort can decrease contraceptive effectiveness by inducing certain metabolic enzymes. Regulatory information advises awareness of the potential risk associated with using drugs or herbal products that may induce or inhibit these metabolic enzymes.


Q: Is it possible for Nortrel 1/35 28 to cause temporary hair loss or thinning?

Hair loss (alopecia) is not generally listed among the most common adverse reactions in the regulatory text for this medication.


Q: Does Nortrel 1/35 28 contain gluten or lactose?

The official description section, which includes inactive ingredients, states that both the active and inert tablets contain lactose monohydrate.

Advertisements

How should Nortrel 1/35 28 be stored and disposed of?

How to Store and Dispose of Nortrel 1/35 28

Nortrel 1/35 (norethindrone and ethinyl estradiol tablets) must be stored under specific conditions to maintain its stability and effectiveness, as defined in regulatory labeling.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F).
Protection Keep the tablets protected from excessive heat and moisture in a cool, dry place.
Container Rule Maintain the tablets in the original blister packaging until immediately prior to use.
Child Safety The medication must be kept out of the sight and reach of children.

Disposal Instructions

Official labeling does not provide unique disposal instructions for this specific product. Unused or expired Nortrel 1/35 should be disposed of following general federal, state, and local pharmaceutical waste handling procedures, such as those provided by community drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nortrel 1/35 28 found in:

A-Z Index: